Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17987142 | 0.84 | CYP11B1 (0.69) | LMNACYP11B1CYP11B2TNFSMN1; SMN2 | |
| SCHEMBL20428044 | 0.82 | CYP11B1 (0.55) | LMNACYP11B1CYP11B2TNFSMN1; SMN2 | |
| SCHEMBL19911313 | 0.81 | CYP11B1 (0.41) | LMNACYP11B1CYP11B2TNFSMN1; SMN2 | |
| SCHEMBL3856820 | 0.81 | ADORA2A (0.47) | LMNACYP11B1CYP11B2TNFSMN1; SMN2 | |
| SCHEMBL3788877 | 0.81 | CYP11B1 (0.58) | LMNACYP11B1CYP11B2TNFSMN1; SMN2 | |
| SCHEMBL4566468 | 0.81 | CYP11B1 (0.58) | LMNACYP11B1CYP11B2TNFSMN1; SMN2 | |
| SCHEMBL4855166 | 0.81 | CYP11B1 (0.58) | LMNACYP11B1CYP11B2TNFSMN1; SMN2 | |
| SCHEMBL9588427 | 0.81 | KMT2A (0.57) | LMNASMN1; SMN2ALDH1A1MEN1CYP1A2 | |
| SCHEMBL10129568 | 0.80 | CYP17A1 (0.45) | LMNACYP11B1CYP11B2SMN1; SMN2ALDH1A1 | |
| SCHEMBL28738319 | 0.79 | SMN1; SMN2 (0.53) | LMNASMN1; SMN2ALDH1A1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9011734-B2 | Ligand exchange thermochromic, (LETC), systems | PLEOTINT, L.L.C. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2082005-B9 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT LLC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8431045-B2 | Ligand exchange thermochromic systems and high ε ligands for same | PLEOTINT, L.L.C. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120292581-A1 | LIGAND EXCHANGE THERMOCHROMIC SYSTEMS AND HIGH E LIGANDS FOR SAME | PLEOTINT, LLC (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2082005-B1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8182718-B2 | Ligand exchange thermochromic systems and high ε ligands for same | PLEOTINT, L.L.C. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2436750-A2 | Ligand exchange thermochromic, (LETC), systems | Pleotint, L.L.C. (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20090283728-A1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT, LLC (US) | 2009-11-19 | — | — | US | disclosed |
| EP-2082005-A1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | Pleotint, L.L.C. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7542196-B2 | Ligand exchange thermochromic, (LETC), systems | PLEOTINT, L.L.C. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7538931-B2 | Ligand exchange thermochromic systems containing exchange metals | PLEOTINT, L.L.C. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7525717-B2 | reversible; laminated; transition metal ion coordinated with a high epsilon ligand and a low epsilon ligand; polymer; separator; variable light transmission windows; polyvinyl butyral; nickel or cobalt iodide ligands; diol, triol or polyol ligands | PLEOTINT, L.L.C. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080106781-A1 | LIGAND EXCHANGE THERMOCHROMIC SYSTEMS CONTAINING EXCHANGE METALS | PLEOTINT, LLC (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080105851-A1 | Exhibiting a reversible change in absorbance of electromagnetic radiation as the temperature of the system is reversibly changed; comprising a transition metal ion and a ligand | PLEOTINT, LLC (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080100902-A1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT, LLC (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080100903-A1 | MULTI-LAYER LIGAND EXCHANGE THERMOCHROMIC SYSTEMS | PLEOTINT, LLC (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008028128-A1 | LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS | PLEOTINT, L.L.C. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | LMNA 1033/4885CYP11B1 640/4885CYP11B2 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.